SWOT Analysis for Astec Lifesciences Ltd. - Threats

Add SWOT widget to your site/app

Relative Outperformance versus Industry over 1 Month

PEG lower than Industry PEG

Relative Outperformance versus Industry over 1 Month

Overbought by Money Flow Index (MFI)

Growth in Net Profit with increasing Profit Margin (QoQ)

Company able to generate Net Cash - Improving Net Cash Flow for last 2 years

Companies with Zero Promoter Pledge

Stock with Low PE (PE < = 10)

Top Gainers

MACD Crossover Below Signal Line

Momentum Trap (DVM)

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score

Low DVM Stocks - Stocks to Exercise Caution On

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Risky Value (DVM)

Low durability companies

Performance of Stocks with Low Trendlyne Durability Score versus Benchmarks

Inefficient use of capital to generate profits - RoCE declining in the last 2 years

Inefficient use of shareholder funds - ROE declining in the last 2 years

Inefficient use of assets to generate profits - ROA declining in the last 2 years

Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years

Declining Revenue every quarter for the past 2 quarters

Low Piotroski Score : Companies with weak financials

Annual net profit declining for last 2 years

Book Value Per Share deteriorating for last 2 years

Weak Momentum: Price below Short, Medium and Long Term Averages

Increasing Trend in Non-Core Income

RSI indicating price weakness

MACD crossed below signal line previous end of day

Declining profitability: Falling ROCE

Stocks Underperforming their Industry Price Change in the Quarter

MFs increased their shareholding last quarter

Promoters increasing shareholding QoQ

Decline in Quarterly Net Profit with falling Profit Margin (YoY)